A cost-utility analysis of an NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected Quality-of-life scores in an economic model of treatment of ovarian cancer

PURPOSE: To estimate quality-of-life (QOL)-adjusted cost-utility with addition of bevacizumab (B) to intravenous paclitaxel/carboplatin (PC) for primary treatment of advanced-stage epithelial ovarian cancer. METHODS: A modified Markov state transition model of 3 regimens evaluated in GOG 218 (PC, PC...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gynecol Oncol
Asıl Yazarlar: Cohn, David E, Barnett, Jason C, Wenzel, Lari, Monk, Bradley J, Burger, Robert A, Straughn, J Michael, Myers, Evan R, Havrilesky, Laura J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512835/
https://ncbi.nlm.nih.gov/pubmed/25449568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.10.020
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller